This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Investors Struggle With Faith In MannKind Prior To FDA Meeting: StockTwits

Stocks in this article: MNKD

NEW YORK (TheStreet) -- Investors on struggled with their faith in MannKind (MNKD) Friday after an analyst's bearish note. The small-cap biotech company has an inhaled diabetes drug that could be worth hundreds of millions annually-if the medication receives FDA approval. If the drug isn't approved, it has little in the pipeline to cushion the blow.

@Dwyatt1985 This is risky here if all goes well surge by 30% if it goes wrong loses 80%

Vincent (@MarketoMarket) Mar. 28 at 11:59 AM

$MNKD again todays price is insignificant. I'm in. make your choice now!

Barna (@barna) Mar. 28 at 12:16 PM

The path to approval might not be easy. In a note to clients, Piper Jaffray analysts wrote that an FDA panel's briefing documents on MannKind's insulin inhaler "Afrezza" suggest an "uphill battle." The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Tuesday April 1 to discuss the drug.

$MNKD MannKind briefing docs suggest 'uphill battle,' says Piper Jaffray Fair assessment.I, too, turned neutral today

Keynesonomics (@Keynesonomics) Mar. 28 at 12:53 PM

MannKind shares had dropped nearly 6% by mid-day, though they recovered some by 1 p.m. EDT. In a report, the FDA said Afrezza is effective in treating Type 2 diabetes but can cause breathing problems. The FDA reviewer also wrote that the drug showed "statistically inferior" blood sugar reduction in patients with Type 1 diabetes compared to other fast acting insulin drugs. The cashtaggers dilemma illustrates a problem with investing in early stage biotech companies with one major, unapproved drug. If the drug is approved, the stock can go up more than 100%. But if the drug fails along the way, there's little reason for investors to keep holding shares, and the stock plummets.

@shanemmas if approved without much label restriction, you can see the stock trading 18-22 but no approval means 50 cents eventually.

fkshen (@fkshen) Mar. 28 at 12:55 PM

At the time of publication the author had no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs